J&J Secures $2.58B Option to Acquire Sail Biomedicines

Johnson & Johnson has entered a collaboration and equity investment agreement with Sail Biomedicines, a Flagship Pioneering company, to advance in vivo CAR T-cell therapies for immune-mediated diseases. As part of the agreement, Johnson & Johnson secured an exclusive option to acquire Sail for $2.58 billion. The companies will jointly advance Sail's lead in vivo CAR T program along with its broader platform technology.

The deal marks Johnson & Johnson's largest investment to date in in vivo cell therapy, building on its existing oncology CAR T franchise with ciltacabtagene autoleucel (Carvykti; Legend Biotech), approved for relapsed or refractory multiple myeloma. Unlike ex vivo CAR T manufacturing, which requires apheresis and genetic modification outside the body before reinfusion, Sail's in vivo approach reprograms immune cells directly inside the patient. Johnson & Johnson previously explored in vivo approaches through a partnership with Kelonia Therapeutics before Kelonia's subsequent acquisition by Eli Lilly.

"People living with serious immune-mediated diseases continue to need treatments that can deliver deeper, more durable disease control," John Reed, MD, PhD, executive vice president, Innovative Medicine Research & Development at Johnson & Johnson, said in a statement. "Sail's innovative platform represents an exciting new approach that seeks to harness the power of CAR T therapy in a simpler, more scalable way."

Sail's eRNA-based in vivo CAR T platform and deal structure

Under the agreement, Johnson & Johnson will make total initial payments of $785 million, including a $465 million equity investment, with an additional $140 million contingent on achievement of development milestones. Sail's lead asset, SAIL-0839, remains in preclinical development, and the company has not disclosed which immune-mediated disease indications it will pursue first. Should Johnson & Johnson exercise its option, the acquisition would bring Sail's full platform into the company's portfolio.

Sail's platform combines its proprietary Endless RNA (eRNA) constructs with targeted nanoparticle delivery and AI-driven product design to direct therapeutic instructions to specific cells inside the body without ex vivo processing. The collaboration includes incentives to expand the approach to additional therapeutic targets beyond the lead program over time.

Pipeline context and manufacturing rationale for in vivo CAR T

The agreement extends a wave of large pharmaceutical investment in in vivo cell therapy platforms over the past 18 months. AbbVie acquired Capstan Therapeutics for $2.1 billion, gaining CPTX2309, an in vivo anti-CD19 CAR T therapy now in phase 1 development for systemic lupus erythematosus and rheumatoid arthritis. Bristol Myers Squibb acquired a preclinical CD19 autoimmune asset through its $1.5 billion takeover of Orbital Therapeutics.

Eli Lilly agreed in April 2026 to pay $3.25 billion upfront for Kelonia Therapeutics, and Gilead Sciences expanded its cell therapy footprint through its $7.8 billion acquisition of Arcellx. Collectively, these deals represent more than $15 billion in disclosed and contingent commitments toward in vivo cell therapy platforms across the industry since early 2025.

Manufacturing logistics remain the central rationale driving pharma interest in the modality. Conventional autologous CAR T-cell therapy requires individualized cell collection, ex vivo genetic engineering, and centralized or point-of-care manufacturing, followed by lymphodepleting chemotherapy before infusion. The ex vivo process can extend treatment timelines to several weeks depending on manufacturing capacity.

In vivo platforms like Sail's aim to reprogram T cells inside the body without apheresis or lymphodepletion, potentially reducing cost, manufacturing complexity, and time to treatment relative to ex vivo approaches. Avoiding lymphodepleting conditioning could also reduce exposure to the infection risk and cytopenias associated with pre-treatment chemotherapy. Because SAIL-0839 remains preclinical, safety and efficacy data in humans have not yet been reported.

Johnson & Johnson has framed the collaboration as an extension of its immunology leadership and broader immune reset strategy across autoimmune and inflammatory disease. Company leadership highlighted the platform's potential to reprogram, rather than merely suppress, the immune response.

John Mendlein, PhD, executive chairman of Sail Biomedicines and executive partner at Flagship Pioneering, said the company looks forward to working with Johnson & Johnson's scientists and leadership toward its shared goal of bringing durable clinical benefit to patients with immune-mediated diseases. The agreements remain subject to customary closing conditions. Johnson & Johnson has separately committed $55 billion toward expanding its US research and manufacturing footprint by 2029, including $1 billion directed toward cell therapy manufacturing operations announced in February 2026.

References

1. Johnson & Johnson announces collaboration with Sail Biomedicines to advance in vivo CAR-T programs and transform autoimmune disease through immune reset. News release. Johnson & Johnson. July 29, 2026. https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-collaboration-with-sail-biomedicines-to-advance-in-vivo-car-t-programs-and-transform-autoimmune-disease-through-immune-reset

2. Sail Biomedicines announces strategic collaboration to develop new class of medicines for in vivo CAR-T. News release. Sail Biomedicines. July 28, 2026. https://www.businesswire.com/news/home/20260728202837/en/Sail-Biomedicines-Announces-Strategic-Collaboration-to-Develop-New-Class-of-Medicines-for-In-Vivo-CAR-T

3. J&J pays Sail $785M, securing option on in vivo CAR-T buyout. Fierce Biotech. July 30, 2026. https://www.fiercebiotech.com/biotech/jj-pays-sail-785m-charting-course-possible-vivo-car-t-buyout